Towards a rational graft-versus-host disease (GVHD) prophylaxis: Rituximab should not be forgotten

Haematologica

Volumn 98, Issue 4, 2013, Pages

  Van Hoef, Marlies E H M ^a  

^a Transplant Creations ^*  (Netherlands)

Author keywords

Graft versus host disease; Hematopoietic cell transplantation; Prophylaxis; Rituximab; Treatment

Indexed keywords

CD20 ANTIBODY; CYCLOPHOSPHAMIDE; FLUDARABINE; METHOTREXATE; RITUXIMAB; TACROLIMUS;

ACUTE LYMPHOBLASTIC LEUKEMIA; CALCINEURIN; FOLLICULAR LYMPHOMA; GRAFT VERSUS HOST REACTION; HUMAN; LETTER; LYMPHOCYTOMA; LYMPHOPROLIFERATIVE DISEASE; MORTALITY; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; PROPHYLAXIS; TRANSPLANTATION;

ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC AGENTS; GRAFT VS HOST DISEASE; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS;

EID: 84875683337     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2012.082271     Document Type: Letter

References (21)

1. Bucher CM, Passweg JR. Towards rational GVHD prophylaxis. Haematologica. 2012;97(12):1779-80.
2. Ratanatharathorn V, Ayash L, Reynolds C, Silver S, Reddy P, Becker M, et al. Treatment of chronic graft-versus-host-disease with anti-CD20 chimeric monoclonal antibody. Biol Blood Marrow Transplant. 2003;9(8):505-11.
3. Canninga-van Dijk MR, van der Straaten HM, Fijnheer R, Sanders CJ, van den Tweel JG, Verdonck LF. Anti CD20 monoclonal antibody treatment in 6 patients with therapy-refractory chronic graft versus host disease. Blood. 2004;104(8):2603-6.
4. Okamoto M, Okano A, Akamatsu S, Ashihara E, Inaba T, Takenaka H, et al. Rituximab is effective for steroid-refractory sclerodermatous chronic graft versus host disease. Leukemia 2006;20(1):172-3.
5. Cutler C, Miklos D, Haesook T, Treisler N, Woo S, Bienfang D, et al. Rituximab for steroid refractory chronic graft versus host disease. Blood. 2006;108(2):756-62.
6. Zaja F, Bacigalupo A, Patriarca F, Stanzani M, Van Lint MT, Fili C, et al. Treatment of refractory chronic graft versus host disease with rituximab: a GITMO study. Bone Marrow Transplant. 2007;40(3):273-7.
7. von Bonin M, Oelschlägel U, Radke J, Stewart M, Ehninger G, Bornhauser M, Platzbecker U. Treatment of chronic steroidrefractory graft versus host disease with low-dose rituximab. Transplantation. 2008;86(6):875-9.
8. Teshima T, Nagafuji K, Henzan H, Miyamura K, Takase K, Hidaka M, et al. Rituximab for the treatment of corticosteriod refractory chronic graft versus host disease. Int J Hematol. 2009;90(2):254-60.
9. Kim SJ, Lee JW, Jung CW, Min CK, Cho B, Shin HJ, et al. Weekly rituximab followed by monthly rituximab treatment for steroid refractory chronic graft versus host disease: results from a prospective multicenter phase II study. Haematologica. 2012;95(11):1935-42.
10. Gutiérrez-Aguirre CH, Cantú-Rodríguez OG, Borjas-Almaguer OD, González-Llano O, Jaime-Pérez JC, Solano-Genesta M, et al. Effectiveness of subcutaneous low-dose alemtuzumab and rituximab combination therapy for steroid-resistant chronic graft-versushost disease. Haematologica. 2012;97(5):717-22.
11. Kharfan-Dabaja MA, Mhaskar AR, Djulbegovic B, Cutler C, Mothy M, Kuman A. Efficacy of rituximab in the setting of steroid refractory chronic graft versus host disease: a systematic review and meta analysis. Biol Blood Marrow Transplant. 2009;15(9):1005-13.
12. Van Hoef MEHM. Risk reduction of chronic graft versus host disease by anti-CD20 treatment (rituximab). Blood. 2005;106: abs 5567.
13. Khouri IF, Saliba RM, Giralt SA, Lee MS, Okoroji GJ, Hagemeister FB. Nonablative allogeneic hematopoietic transplantation as adoptive immunotherapy for indolent lymphoma: low incidence of toxicity, acute graft versus host disease and treatment related mortality. Blood. 2001;09(13):3595-9.
14. Kebriaei P, Saliba RM, Ma C, Ippoliti C, Couriel DR, de Lima M, et al. Allogeneic hematopoietic stem cell transplantation after rituximab containing myeloablative preparative regimen for acute lymphoblastic leukemia. Bone Marrow Transplant. 2006;38(8):203-9.
15. Khouri IF, McLaughlin P, Saliba RM, Hosing C, Korbling M, Lee MS, et al. Eight year experience with allogeneic stem cell transplantation for relapsed follicular lymphoma after nonmyeloablative conditioning with fludarabine, cyclophosphamide and rituximab. Blood. 2008;111(12):5530-6.
16. Christopeit M, Schutte V, Theurich S, Weber T, Grothe W, Behre G. Rituximab reduced the incidence of acute graft versus host disease. Blood. 113(3):3130-1.
17. Ratanatharathorn V, Logan B, Wang D, Horowitz M, Uberti JP, Ringden O, et al. Prior rituximab correlates with less acute graft versus host disease and better survival in B-cell lymphoma patients who received allogeneic peripheral blood stem cell transplantation. Br J Haematol. 2009;145(6):816-24.
18. van Dorp S, Pietersma F, Wölfl M, Verdonck LF, Petersen EJ, Lokhorst HM, et al. Rituximab treatment before reduced intensity conditioning transplantation associates with a decreased incidence of extenstive chronic GVHD. Biol Blood and Marrow Transplant. 2009;15(6):671-8.
19. Crocchiolo R, Catagna L, El Cheikh J, Helvig A, Fuerst S, Faucher C, et al. Prior rituximab administration is associated with reduced rate of acute graft versus host disease after in vivo T-cell depleted transplantation in lymphoma patients. Exp Hematol. 2011;39(9):892-6.
20. Dominetto A, Tedone E, Soracco M, Bruno B, Raiola AM, Van Lint MT, et al. In vivo B-cell depletion with rituximab for alternative donor hematopoietic SCT. Bone Marrow Transplant. 2012;47(1): 101-6.
21. Arai S, Saraf B, Narashimhan B, Chen GL, Jones CD, Lowsky R, et al. Prophylactic rituximab after allogeneic transplantation decreases B-cell alloimmunity with low chronic graft versus host disease incidence. Blood. 2012;119(25):6145-54.